Eli Lilly And Company (LLY): Today's Featured Drugs Laggard

Eli Lilly and Company ( LLY) pushed the Drugs industry lower today making it today's featured Drugs laggard. The industry as a whole closed the day up 0.7%. By the end of trading, Eli Lilly and Company fell 42 cents (-0.9%) to $43.74 on light volume. Throughout the day, 3.5 million shares of Eli Lilly and Company exchanged hands as compared to its average daily volume of six million shares. The stock ranged in price between $43.71-$44.13 after having opened the day at $44.13 as compared to the previous trading day's close of $44.15. Other company's within the Drugs industry that declined today were: Exelixis ( EXEL), down 13.1%, AVEO Pharmaceuticals ( AVEO), down 10.3%, Senesco Technologies ( SNT), down 9.7%, and Cytori Therapeutics ( CYTX), down 7.9%.

Eli Lilly and Company discovers, develops, manufactures, and sells pharmaceutical products worldwide. Eli Lilly and Company has a market cap of $50.27 billion and is part of the health care sector. The company has a P/E ratio of 12, equal to the average drugs industry P/E ratio and below the S&P 500 P/E ratio of 17.7. Shares are up 5.5% year to date as of the close of trading on Friday. Currently there are three analysts that rate Eli Lilly and Company a buy, three analysts rate it a sell, and 11 rate it a hold.

TheStreet Ratings rates Eli Lilly and Company as a buy. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, attractive valuation levels, solid stock price performance, expanding profit margins and notable return on equity. We feel these strengths outweigh the fact that the company has had somewhat weak growth in earnings per share.

On the positive front, Biosante Pharmaceuticals ( BPAX), up 22.4%, iBio ( IBIO), up 19.3%, OxiGene ( OXGN), up 17.6%, and Chemocentryx ( CCXI), up 15.6%, were all gainers within the drugs industry with Celgene Corporation ( CELG) being today's featured drugs industry leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).